Houston, TX, June 02, 2022 (GLOBE NEWSWIRE) -- NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M fundraising, co-led by AstraZeneca-CICC Fund, CR-CP Life Science...
Marina Biotech is a clinical stage biotechnology company focused on development and commercialization of therapeutic products for rare diseases based on RNA interference (RNAi). The company is developing proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds intended to trigger various RNA-based mechanisms of action including RNA interference, microRNA replacement therapy, microRNA inhibition and mRNA translational inhibition, respectively.
Marina Biotech
Bothell, WA
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.